Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...
The PI3K inhibitor market is becoming increasingly ... positions it as a potentially best-in-class PI3Ka inhibitor. This superior efficacy compared to current standards of care could drive strong ...
A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs ...
Cofounded by Dr. Siddhartha Mukherjee and Reid Hoffman, Manas AI leverages proprietary AI, generative computational chemistry ...
Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated ...
A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.
"It's especially exciting to integrate world-class AI capabilities with groundbreaking ... Dr. Lew Cantley (Harvard University), discoverer of PI3K and PTEN, scientific founder of Agios Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback